Publications

BibTex format

@article{Fox:2016,
author = {Fox, J and Tiraboschi, JM and Herrera, C and Else, L and Egan, D and Dickinson, L and Jackson, A and Olejniczak, N and Back, D and Khoo, S and Shattock, R and Boffito, M},
journal = {JAIDS-Journal of Acquired Immune Deficiency Syndromes},
pages = {252--257},
title = {Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis},
volume = {73},
year = {2016}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - To investigate the pharmacokinetics/pharmacodynamics ofsingle-dose maraviroc 300 mg in HIV-1 exposure compartments.Maraviroc concentrations in blood, secretions (vaginal, urethral, oral,and rectal), and tissue (vaginal and rectal) were measured, and ex vivochallenge was performed in 54 healthy volunteers to study protectionfrom HIV infection. Maraviroc Cmax occurred within 4 hours inmost compartments. Concentrations from 4 to 72 hours were aboveintracellular (IC) IC90 in all compartments, range 15–8095 ng/mL. MeanAUC0-72 compartment-to-plasma ratios were highest in the rectum (45–819) and urethra (144) compared with the female genital tract (1.6–4.8)and saliva (0.2). No sex differences in AUC0-72 or Cmax were observed.No ex vivo protection from HIV-1BaL occurred in rectal or vaginaltissue. Despite high and sustained concentrations, single-dose maravirocwas not protective against ex vivo challenge of vaginal/rectal tissue.
AU  - Fox,J
AU  - Tiraboschi,JM
AU  - Herrera,C
AU  - Else,L
AU  - Egan,D
AU  - Dickinson,L
AU  - Jackson,A
AU  - Olejniczak,N
AU  - Back,D
AU  - Khoo,S
AU  - Shattock,R
AU  - Boffito,M
EP  - 257
PY  - 2016///
SN  - 1525-4135
SP  - 252
TI  - Pharmacokinetic/Pharmacodynamic Investigation of Single-Dose Oral Maraviroc in the Context of HIV-1 Pre-exposure Prophylaxis
T2  - JAIDS-Journal of Acquired Immune Deficiency Syndromes
VL  - 73
ER  -

Download

DrCarolinaHerrera

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)